Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE. - Matikas A; Naume B; Wildiers H; Sonke G; Dieci MV; Karakatsanis A; Andersson A; Barnekow E; Kessler LE; Einbeigi Z; Killander F; Linderholm B; et al. (BMJ open, 2025)